Annual Total Long Term Liabilities
$77.91 M
+$32.51 M+71.59%
31 December 2023
Summary:
Monte Rosa Therapeutics annual total long term liabilities is currently $77.91 million, with the most recent change of +$32.51 million (+71.59%) on 31 December 2023. During the last 3 years, it has risen by +$9.08 million (+13.19%). GLUE annual total long term liabilities is now at all-time high.GLUE Long Term Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Long Term Liabilities
$67.98 M
-$9.11 M-11.82%
30 September 2024
Summary:
Monte Rosa Therapeutics quarterly total long term liabilities is currently $67.98 million, with the most recent change of -$9.11 million (-11.82%) on 30 September 2024. Over the past year, it has increased by +$23.01 million (+51.17%). GLUE quarterly long term liabilities is now -70.71% below its all-time high of $232.13 million, reached on 31 March 2021.GLUE Quarterly Long Term Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
GLUE Long Term Liabilities Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +71.6% | +51.2% |
| 3 y3 years | +13.2% | +3297.4% |
| 5 y5 years | - | - |
GLUE Long Term Liabilities High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | at high | +3480.6% | -12.8% | +3297.4% |
| 5 y | 5 years | at high | +3480.6% | -70.7% | +4518.3% |
| alltime | all time | at high | +3480.6% | -70.7% | +4518.3% |
Monte Rosa Therapeutics Long Term Liabilities History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | $67.98 M(-11.8%) |
| June 2024 | - | $77.09 M(+5.7%) |
| Mar 2024 | - | $72.93 M(-6.4%) |
| Dec 2023 | $77.91 M(+71.6%) | $77.91 M(+73.3%) |
| Sept 2023 | - | $44.97 M(-2.0%) |
| June 2023 | - | $45.87 M(+2.4%) |
| Mar 2023 | - | $44.79 M(-1.4%) |
| Dec 2022 | $45.41 M | $45.41 M(+1.5%) |
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2022 | - | $44.72 M(-7.3%) |
| June 2022 | - | $48.23 M(+531.3%) |
| Mar 2022 | - | $7.64 M(+251.1%) |
| Dec 2021 | $2.18 M(-96.8%) | $2.18 M(+8.7%) |
| Sept 2021 | - | $2.00 M(+35.9%) |
| June 2021 | - | $1.47 M(-99.4%) |
| Mar 2021 | - | $232.13 M(+237.2%) |
| Dec 2020 | $68.83 M(+263.2%) | $68.83 M |
| Dec 2019 | $18.95 M | - |
FAQ
- What is Monte Rosa Therapeutics annual total long term liabilities?
- What is the all time high annual total long term liabilities for Monte Rosa Therapeutics?
- What is Monte Rosa Therapeutics annual total long term liabilities year-on-year change?
- What is Monte Rosa Therapeutics quarterly total long term liabilities?
- What is the all time high quarterly long term liabilities for Monte Rosa Therapeutics?
- What is Monte Rosa Therapeutics quarterly long term liabilities year-on-year change?
What is Monte Rosa Therapeutics annual total long term liabilities?
The current annual total long term liabilities of GLUE is $77.91 M
What is the all time high annual total long term liabilities for Monte Rosa Therapeutics?
Monte Rosa Therapeutics all-time high annual total long term liabilities is $77.91 M
What is Monte Rosa Therapeutics annual total long term liabilities year-on-year change?
Over the past year, GLUE annual total long term liabilities has changed by +$32.51 M (+71.59%)
What is Monte Rosa Therapeutics quarterly total long term liabilities?
The current quarterly long term liabilities of GLUE is $67.98 M
What is the all time high quarterly long term liabilities for Monte Rosa Therapeutics?
Monte Rosa Therapeutics all-time high quarterly total long term liabilities is $232.13 M
What is Monte Rosa Therapeutics quarterly long term liabilities year-on-year change?
Over the past year, GLUE quarterly total long term liabilities has changed by +$23.01 M (+51.17%)